Difference between revisions of "Semuloparin (AVE-5026)"
Jump to navigation
Jump to search
m |
Warner-admin (talk | contribs) m (Text replacement - "Category:Drug index" to "Category:Drugs") |
||
| Line 11: | Line 11: | ||
<references/> | <references/> | ||
| − | [[Category: | + | [[Category:Drugs]] |
[[Category:Hematology medications]] | [[Category:Hematology medications]] | ||
[[Category:Subcutaneous medications]] | [[Category:Subcutaneous medications]] | ||
Revision as of 23:19, 13 June 2018
General information
Class/mechanism: Hemisynthetic ultra low molecular weight heparin (ULMWH), binds to antithrombin III, accelerating its activity and inhibiting factor Xa, factor IIa, and thrombin.[1][2]
Route: SC
Extravasation: n/a
Patient drug information
No information available.
References
- ↑ Semuloparin (AVE5026) manufacturer's website
- ↑ Agnelli G, George DJ, Kakkar AK, Fisher W, Lassen MR, Mismetti P, Mouret P, Chaudhari U, Lawson F, Turpie AG; SAVE-ONCO Investigators. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med. 2012 Feb 16;366(7):601-9. link to original article PubMed